 |
1 Disease |  |
0 Trials |
|
0 Trials |  |
12 News |  |
- | MMI-0100 / Moerae Matrix, Teva
Journal: Involvement of mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MK2) in endothelial dysfunction associated with pulmonary hypertension. (Pubmed Central) - Dec 16, 2021
These findings proved that MK2 is involved in endothelial dysfunction, and its inhibition may be beneficial for endothelial function in PH.
- | MMI-0100 / Moerae Matrix, Teva
Journal: Intranasal MMI-0100 Attenuates Aβ- and LPS-Induced Neuroinflammation and Memory Impairments via the MK2 Signaling Pathway. (Pubmed Central) - Nov 12, 2020
MMI-0100 attenuates Aβ- and LPS-induced neuroinflammation and memory impairments via the MK2 signaling pathway. Meanwhile, these data suggest that the MMI-0100/MK2 system may provide a new potential target for treatment of AD.
- | low molecular weight dextran sulfate (ILB) / TikoMed, MMI-0100 / Moerae Matrix, Teva
Preclinical, Journal, IO Biomarker: MMI-0100 Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice through Targeting MK2 Pathway. (Pubmed Central) - Jan 16, 2020
The anti-inflammatory effects of MMI-0100 on DSS-induced colitis were achieved by down-regulating the phosphorylation level of MK2, IκBα and p65 protein. The current study clearly demonstrates a protective role for MMI-0100 in experimental IBD.
- | MMI-0100 / Moerae Matrix, Teva, bleomycin / Generic Mfg., BMS
Journal: MK2 Inhibition Attenuates Fibroblast Invasion and Severe Lung Fibrosis. (Pubmed Central) - Nov 21, 2019
Conditional deletion of MK2 in fibroblasts attenduated bleomycin-induced lung fibrosis. These data provide evidence that MK2 has a role in fibroblast invasion and fibrosis and may be a novel therapeutic target in pulmonary fibrosis.
- | MMI-0100 / Moerae Matrix, Teva
Journal: MMI-0100 ameliorates lung inflammation in a mouse model of acute respiratory distress syndrome by reducing endothelial expression of ICAM-1. (Pubmed Central) - Apr 23, 2019
The mRNA and protein expression of ICAM-1 in the LPS group was significantly higher than in the control group in mouse PMVECs, and the ICAM-1 level was reduced after the administration of MMI-0100. These data indicate that MMI-0100 ameliorates lung inflammation in a mouse model of ARDS by reducing endothelial expression of ICAM-1.
- MMI-0100 / Moerae Matrix, Teva
Enrollment closed, Phase classification, Trial primary completion date: LPS: Phase 1a Study in Healthy Smokers to Investigate the Effect With MMI-0100 on Airway Inflammation in Induced Sputum After Challenge With Inhaled Lipopolysaccharide (clinicaltrials.gov) - Apr 7, 2017
P1a, N=20, Active, not recruiting, Sponsor: Moerae Matrix, Inc.
These data indicate that MMI-0100 ameliorates lung inflammation in a mouse model of ARDS by reducing endothelial expression of ICAM-1. Recruiting --> Active, not recruiting | Phase classification: P1 --> P1a | Trial primary completion date: Oct 2015 --> Mar 2016
- MMI-0100 / Moerae Matrix, Teva
New P1 trial: LPS: Phase 1a Study in Healthy Smokers to Investigate the Effect With MMI-0100 on Airway Inflammation in Induced Sputum After Challenge With Inhaled Lipopolysaccharide (clinicaltrials.gov) - Aug 4, 2015
P1, N=20, Recruiting, Sponsor: Moerae Matrix, Inc.